US Biotech and Essential Science Sign Agreement Around Commercialisation of Clinical Stage Immunomodulator

Undisclosed, US & Edzell, UK 27 Oct 2006 - An undisclosed US biotech company and Essential Science Ltd, the UK technology exploitation company, today announced a collaborative agreement to exploit an immunomodulator co-therapy in major therapeutic markets. Using extensive market knowledge and wide contact network within small to large anti-infective companies, Essential Science will add significant value by focusing on the non-core market opportunities for the candidate, particularly in the infectious disease area.

About Essential Science

Essential Science Ltd supports technology clients in the development and exploitation of new technologies across the Life Science marketplace. As the number of available technologies grows and client success becomes increasingly dependent on the identification and exploitation of the right technologies, its experienced team, supported by an extensive associate network, is focused on establishing the partnerships that bring client technologies to market faster and more effectively.

Enquiries  ::  Neil Murray  ::  +44 1356 648941  ::  neil@essentialscience.co.uk

Date  ::  Sunday 26 November 2006